To elucidate whether introduction of transgenic CD8α receptor adequately rescues TEG011 reactivity of non-tumor reactive CD4-transduced cells once delivered by the very same vector, we co-cultured tumor target HLA-A*24:02-transduced CML tumor cells (K562), SW480, and EBV-LVL cells with either CD4+ TEG011_CD8α, CD4+ TEGLM1_CD8α, or CD4+ TEG011 (without introduction of the CD8α receptor). The gene discussed is HLA-A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.